Results From 171 screened subjects, the final cohort included 86 patients with CIS, with a
median follow-up of 46.1 months (range 2.2–78.7 months). Online supplementary file 1 (…

In patients with relapsing-remitting multiple sclerosis (MS), IVIG was shown to reduce the
relapse rate and progression of disability. In patients with chronic progressive MS, a beneficial …

… 13 multiple sclerosis centres completed a questionnaire every time they assessed multiple
sclerosis … Our study confirms the therapeutic attitude of multiple sclerosis specialists in treating …

… Three different beta interferon products are registered for the treatment of relapsing-remitting
multiple sclerosis (MS). Their efficacy has been proven in several multicentre, controlled …

… (2007), all the studies mentioned above were single center studies. Multi-center studies of
MS as currently implemented for phase 3 clinical trials require large sample sizes and usually …

… training, we were not able to ascertain compliance in this study. In summary, in this prospective
multicentre study, we have demonstrated that in Australian tertiary centres with specialist …

… Data from our multi-center study are in line with recently published data from a small
prospective study that examined efficacy of natalizumab in patients who failed IFN-beta or GA [17]. …

… of childhood-onset multiple sclerosis and adolescent-onset multiple sclerosis and to … ,
multicentric study. We reviewed data of all patients with multiple sclerosis younger than 18 …

… This multicentre study confirms that a high proportion MS patients have CCSVI, as assessed
by venous Doppler sonography. The relative high between-centre variability, particularly of …

Background Multiple sclerosis (MS) is now recognized as a multifactorial disease in which
genetic and environmental factors intervene. Considerable efforts have been made to identify …